The Pharmacokinetic and clinical Observations in PeoPle over fifty (POPPY) Study was initiated in 2013 as the first large-scale study to assess clinical outcomes of people living with HIV (PLWH) over the age of 50 in England and Ireland. Discussions around the management of HIV as a chronic disease have been ongoing (1-5). However, some recent studies have suggested a possible acceleration of the aging process in PLWH with reported increases in the rates of several comorbidities, including cardiovascular disease (CVD), cancers, cognitive disorders, end-stage liver and renal disease and frailty and fracture risk (6-10). The primary aims of the study were therefore: (i) to describe the burden of clinical conditions in older PLWH; ii) to investigate whether the burden of comorbidities is increased in PLWH compared to demographically similar HIV-negative people; and iii) to describe the outcomes of and resources required to treat some of the more common comorbidities that were expected to occur in older PLWH to see whether these also appeared to differ between those with and without HIV. An additional, related, aim of the study is to investigate the impact of age on the concentrations of the different antiretroviral agents in the blood among PLWH.
Why was the cohort set up?
The Pharmacokinetic and clinical Observations in PeoPle over fifty (POPPY) Study was initiated in 2013 as the first large-scale study to assess clinical outcomes of people living with HIV (PLWH) over the age of 50 in England and Ireland. Discussions around the management of HIV as a chronic disease have been ongoing (1) (2) (3) (4) (5) . However, some recent studies have suggested a possible acceleration of the aging process in PLWH with reported increases in the rates of several comorbidities, including cardiovascular disease (CVD), cancers, cognitive disorders, end-stage liver and renal disease and frailty and fracture risk (6) (7) (8) (9) (10) . The primary aims of the study were therefore: (i) to describe the burden of clinical conditions in older PLWH; ii) to investigate whether the burden of comorbidities is increased in PLWH compared to demographically similar HIV-negative people; and iii) to describe the outcomes of and resources required to treat some of the more common comorbidities that were expected to occur in older PLWH to see whether these also appeared to differ between those with and without HIV. An additional, related, aim of the study is to investigate the impact of age on the concentrations of the different antiretroviral agents in the blood among PLWH.
It is hoped that the study findings will contribute to the development and implementation of evidence-based recommendations for the optimal management and clinical monitoring of older PLWH. Study results will also contribute to the design of future studies for the treatment of diseases associated with ageing in this population. 
Funding and ethical approval

Who is in the cohort?
POPPY is a multicentre, prospective, observational study initially funded for three study visits which occur annually. To address the primary aims of the study, three groups of individuals were invited to participate in the study: PLWH aged >50 years; PLWH aged <50 years; and a group of HIV-negative controls aged >50 years. All participants were of white or black African ethnicity and had acquired HIV via a sexual route (either sex between men or sex between men and women). Those recruited in the younger group of PLWH were frequency-matched to the group of older PLWH on gender, ethnicity, sexual orientation and participating clinic. HIV-negative participants were required to have a documented negative HIV test in the past 6 months or at the time of screening; this group was frequency matched to the older PLWH group on age, gender, ethnicity, sexual orientation and geographical location (in or out of London). to ensure that PLWH who participated in the study were broadly representative of PLWH in participating centres. The number of people to be recruited from each centre was agreed in advance with study investigators and was based on an agreed proportion of the total numbers of attendees at each clinic to ensure feasibility.
Identifying potential eligible participants and recruitment
Our goal was to recruit a study cohort that did not over-represent those who either attended clinic more frequently or who were more regular participants in research studies. To attempt to achieve this, each clinic's list of eligible attendees was ordered randomly and clinics were asked to approach those at the top of the list first, before moving further down the list should insufficient numbers at the top of the list agree to participate. Whilst not a perfect approach, this was felt to be a recruitment method that would be feasible within a busy clinic setting.
Where possible, HIV-negative participants were selected from similar underlying populations (e.g. from genitourinary medicine clinics for the white men who have sex with men participants, and local community settings for those of black African origin).
The original planned sample size was 2000 (1000 older PLWH, 500 younger PLWH and 500 HIVnegative controls) and was chosen pragmatically to reflect what was felt to be feasible given the number of people receiving care at each of the clinics. Given time constraints, however, recruitment was stopped once 1376 participants had been recruited (699 older PLWH, 374 younger PLWH and 304 HIV-negative controls) as it was felt that the additional effort that would be required to increase the sample size further would not be balanced by an increased amount of information in the cohort.
Characteristics of cohort
The total cohort includes 1377 participants. Baseline demographic, clinical and lifestyle characteristics are shown in Table 1 . In brief, 1109 (80.5%) of the cohort were male (88.0%, 80.8% 6 and 64.0% in older PLWH, younger PLWH and HIV-negative controls, respectively), 963 (70.0%) defined themselves as men who have sex with men (MSM) and 1175 (85.3%) had a white ethnic background. The median age was 56 (Q1-Q3: 53-62) for the older PLWH, 43 (37-47) for the younger PLWH and 58 (53-63) for the HIV negative controls and almost 45% were single (54.0%, 31.0% and 15.0%, respectively). Finally, around two-thirds (64.7%) of participants are born to parents from the UK/Ireland.
[ Table 1 here]
To assess the representativeness of the older cohort (the younger cohort of PLWH was selected to be demographically similar to the older cohort, rather than to be representative of the UK HIV epidemic), we compared selected characteristics of the older cohort of PLWH within the UK POPPY sites (n=667/699) to individuals attending the same clinics who would have been eligible for participation in the study (based on age, ethnicity and exposure group) at the start of 2013, but who were not included (n=4786, Table 2 ). Information for the latter group was obtained from the UK CHIC study. Individuals who were included in POPPY were slightly more likely to be male (88.0% vs.
85.4%), were more likely to report HIV infection through sex between men (79.8% vs. 70.4%) and to be of white ethnicity (86.4% vs. 79.5%) than non-participating individuals. The median age of the two groups was, however, similar (55 vs. 54 years) as were the proportions of individuals exposed to ART (90.9% vs. 89.6%) and the median CD4 count on 1 st January 2013 (590 cells/mm 3 in each group).
Absolute differences in the viral load and nadir CD4 cell count between the two groups were small.
[ Table 2 here]
How often have they been followed up?
The current protocol entails the following study visits: a screening visit/Visit 1 (baseline) conducted Information on family history of clinical conditions is collected along with current and historic use of antiretroviral medication, for both the older and younger PLWH. Gender-specific information has been collected for pregnancies and screening for cervical and breast cancer for women and anal cancer screening for men. Cognitive function is assessed at baseline and year 2 using specific memory and cognitive testing assessing cortical and sub-cortical function and a detailed pain assessment reports regional and widespread pain using a validated mannequin. A full dual x-ray 8 absorptiometry (DXA) scan is performed at baseline and year 2. Local scanners are used for measuring bone mineral density (BMD) to evaluate bone health and determine the likelihood of osteoporosis or bone fractures. To supplement this, information is also captured on any falls that the participant has experienced over the previous year, and on factors that will permit an assessment of falls and frailty risk.
[Box 1 here]
Blood (serum, plasma, and peripheral blood mononuclear cells (PBMC)) are taken for storage and for pharmacokinetic analysis at baseline and year 2; it is planned that these will be used for subsequent projects of the potential pathogenic mechanisms underlying age-related diseases. Plasma of 4-5 mL 
What has been found? Key findings and publications
Given the broad-subject information collected through POPPY study, a long list of projects are involved, investigating the association of aging with several co-morbidities. Future ongoing and planned projects will involve studies of: sleeping patterns, muscle biopsy, pharmacokinetic and DDIs, cerebrovascular and cardiovascular disease, cognitive analysis, the menopause in women living with HIV, hepatic steatosis, respiratory events, bone health and fractures, mental health, and chronic pain.
A recent project within POPPY investigated the agreement of different approaches used to define cognitive impairment in HIV (13) . The Frascati criteria, global deficit score (GDS) and multivariate normative comparison (MNC) were used to define cognitive impairment. We found that the different criteria of cognitive impairment show fair diagnostic agreement in PLWH and that those meeting all three criteria had the highest rates of symptomatology. In another POPPY publication, Underwood et al. (14) found weak associations between the same three criteria of cognitive impairment and patient-reported measures of physical/mental functioning in older PLWH.
What are the main strengths and weaknesses?
Currently, there is no large study on HIV and the effects of ageing in the UK and Ireland.
Internationally, several research groups have developed initiatives in this area, but most of these A limitation of the POPPY study is the lack of a young HIV-negative group that would facilitate a direct comparison with the younger group of PLWH, and an over-representation of white women among the HIV-negative control group. Due to time and budget constrains this was not feasible.
Future studies should consider incorporating such a group in their design in order to understand patterns and behaviours as well as similarities and differences with younger PLWH.
Can I get hold of the data? Where can I find out more?
Further information for the cohort collaboration policy can be obtained from Professor Caroline Funding: This work is supported by investigator initiated grants from Bristol-Myers Squibb, Gilead
Sciences, Janssen-Cilag, Merck Sharp and Dohme, and ViiV Healthcare.
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Profile in a nutshell
The POPPY Study is the first large-scale study to assess clinical outcomes of people living with HIV (PLWH) over the age of 50 in England and Ireland. 
